Exane Derivatives’s Bloom Energy BE Stock Holding History

Exane Derivatives’s Portfolio BE Stock Details BE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,278	Closed	-$176K	–	804
2022 Q1	$176K	Sell	7,278 -170	-2%	-$3.32K	0.05%	371
2021 Q4	$163K	Sell	7,448 -2,134	-22%	-$54K	0.04%	371
2021 Q3	$179K	Sell	9,582 -57	-0.6%	-$1.21K	0.04%	416
2021 Q2	$213K	Buy	+9,639	New	+$234K	0.05%	378
2021 Q1	–	Sell	-14,209	Closed	-$407K	–	922
2020 Q4	$407K	Buy	+14,209	New	+$303K	0.12%	196

Other funds holding BE

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Exane Derivatives's BE Position: Q2 2022 in Review

Exane Derivatives sold out of Bloom Energy (BE) in Q2 2022, closing a stake of 7,278 shares — an estimated $176K sold.

Exane Derivatives first reported a position in BE in Q4 2020 and held it in 5 quarters. The position peaked at $407K in Q4 2020. 291 funds tracked by Wall St. Rank hold BE as of Q2 2022.

Exane Derivatives reported no remaining Bloom Energy position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 7,278 Bloom Energy shares in Q2 2022, an estimated $176K.
Exane Derivatives first reported a position in Bloom Energy in Q4 2020 and held it in 5 quarters.
Exane Derivatives's Bloom Energy position peaked at $407K in Q4 2020.
291 funds tracked by Wall St. Rank held Bloom Energy as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.